Companion Diagnostics Market Poised for Robust Growth Through 2029
The global Companion Diagnostics Market is experiencing rapid expansion as precision medicine continues to reshape modern healthcare. According to industry projections, the market is expected to grow from USD 7.5 billion in 2024 to USD 13.6 billion by 2029, registering a CAGR of 12.6% during the forecast period. Companion diagnostics (CDx) have become an essential component in personalized medicine, enabling clinicians to identify the most suitable therapies for individual patients based on genetic, molecular, or biomarker analysis. As targeted therapies gain momentum across oncology, cardiology, neurology, and infectious diseases, companion diagnostics are increasingly becoming indispensable for drug development and patient management. Download PDF Brochure What are Companion Diagnostics? Companion diagnostics are medical devices or laboratory tests designed to determine whether a patient is likely to benefit from a specific therapeutic product. These tests analyze biomarkers,...